New drug type developed to kill lymphoma cells
May 11th, 2010 - 5:05 pm ICT by ANIWashington, May 11 (ANI): Scientists have developed a new type of drug designed to kill non-Hodgkin lymphoma tumour cells.
The breakthrough could lead to potential non-toxic therapies for cancer patients.
The researchers, including Dr. Ari Melnick, of Weill Cornell Medical College, Dr. Alexander MacKerell, of the University of Maryland and Dr. Gilbert Prive, of the University of Toronto, have identified a drug that targets an oncogene known as BCL6.BCL6 functions as a master regulatory protein.
“It’s a protein that controls the production of thousands of other genes. Because of that, it has a very profound impact on cells and is required for lymphoma cells to survive and multiply,” said Melnick.
BCL6 causes the majority of diffuse large B cell lymphomas, the most common form of non-Hodgkin lymphoma.
Currently, about 60 percent of diffuse large B cell lymphomas can be cured with chemo-immunotherapy, said Melnick.
“The hope is that we can improve that to a higher percent, and in the long term reduce the need for chemotherapy,” he added.
Traditional cancer drugs target enzymes, which have small pockets on their surfaces that can be blocked with molecules.
Until now, pharmaceutical companies have been reluctant to create drugs that target a protein like BCL6 because they function through a different mechanism involving interactions with cofactor proteins involving extensive protein surfaces.
“And because the real estate covered by these interactions is so large, the drug companies have viewed these as being not druggable targets,” said Melnick.
The researchers could identify a “hot spot” on BLC6 that they predicted would play a critical role in protein interactions.
They showed that their BCL6 inhibitor drug was specific to BCL6, and did not block other master regulatory proteins.
The drug had powerful lymphoma killing activity and yet was non-toxic to normal tissues.
“This is the first time a drug of this nature has been designed and it shows that it’s not actually impossible to target factors like BCL6,” he said.
Emerging data from other investigators suggests that BCL6 is important in many other tumor types, including forms of leukemia.
The study has been published in a recent issue of Cancer Cell. (ANI)
- Boffins design new class of drug that kills lymphoma cells - Apr 15, 2010
- Compound that kills lymphoma cells discovered - Apr 13, 2010
- Novel therapeutic target for non-Hodgkin's lymphoma identified - Nov 23, 2009
- New discovery may explain how certain cancers develop - May 28, 2010
- Link between breast implants and rare form of cancer confirmed - Apr 20, 2011
- Long-term statin 'unlikely to increase cancer risk' - Nov 10, 2010
- How two proteins fuse together to trigger cancer - Jan 28, 2011
- Biophysicist attempts to block protein to prevent breast, prostate cancer - Apr 20, 2011
- Smoking, obesity, alcohol affect survival of non-Hodgkin's lymphoma patients - May 14, 2010
- New strategy to fight cancer drug resistance discovered - Jun 21, 2010
- Happy to be alive after cancer treatment: Puerto Rican singer - Jun 21, 2011
- Vitamin K may help keep non-hodgkin lymphoma at bay - Apr 20, 2010
- Microsoft co-founder Paul Allen diagnosed with cancer - Nov 17, 2009
- India, China making inroads in biotech drugs: NYT - Sep 19, 2011
- Seaweed extract may help treat lymphoma - Mar 11, 2010
Tags: b cell, cancer drugs, cancer patients, cell lymphomas, college dr, cornell medical college, dr alexander, dr gilbert, immunotherapy, lymphoma cells, melnick, non hodgkin lymphoma, protein interactions, protein surfaces, regulatory protein, regulatory proteins, target, university of toronto, weill cornell medical, weill cornell medical college